MK-4830 for Small Cell Lung Carcinoma
This study is evaluating whether investigational agents can be used in combination with pembrolizumab and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage small cell Lung Cancer (ES-SCL
See full descriptionAbout the trial for Small Cell Lung Carcinoma
Treatment Groups
This trial involves 3 different treatments. MK-4830 is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether MK-4830 will improve 2 primary outcomes and 7 secondary outcomes in patients with Small Cell Lung Carcinoma. Measurement will happen over the course of Baseline, Week 19.
Patient Q & A Section
How many people get small cell lung carcinoma a year in the United States?
The true incidence of SCLC in the United States is unknown, but estimates range from 25 to 150 cases per 100,000 population. A study in 1983 found that 30% of the SCLC cases examined were diagnosed at stage I and II, while 10% were diagnosed at stage III. In general, in the United States the pathologic staging of SCLC is well correlated with prognosis. The significance of stage IB and II disease remains unclear. Although this study was performed over 20 years ago, demographic trends over the last decade suggest an increasing frequency and a later age of diagnosis of SCLC.
What is the survival rate for small cell lung carcinoma?
Although there has been some improvement in survival rates, the 5-year survival rate remains poor. This is likely due to low number of cases treated in hospitals, which could affect treatment outcome. Since SCLC is rare in most countries, lack of adequate diagnostic resources could be one of the reasons for this poor prognosis. Survival rates are higher when the disease is diagnosed early and staged appropriately. Treatment options include surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and palliative care. Palliative care should be offered to patients who are unable to undergo curative therapies.
Does small cell lung carcinoma run in families?
Data from a recent study of this study do not support a familial susceptibility to SCLC. Considering the low prevalence of SCLC in the general population, we recommend caution in applying these findings to the general population.
What are the chances of developing small cell lung carcinoma?
The New York Cancer Registry indicated a significant increase in SCLC incidence over a time frame of 3 decades, particularly among non-Hispanic white males aged 50–69 years old. Findings from a recent study has shown a significant association between smoking and SCLC. Findings from a recent study support the need for further investigations to identify risk factors involved in the development of SCLC.
What is the latest research for small cell lung carcinoma?
There are many immunotherapies for SCLC; they could provide an additional option for patients who have no good response to chemotherapy. The choice of therapeutic schedule depends upon which drug is used as well as the stage of disease.
Have there been other clinical trials involving mk-4830?
MK-4830 has not undergone any phase III clinical trial in SCLC. However, several other agents have undergone clinical trials in SCLC, including MK-4870, MK-4658, MK-7508, and MK-1791. These studies showed that MK-4870 was well tolerated and was moderately active in patients with SCLC. However, more data are needed regarding the efficacy of MK-4870 compared to MK-4830 in patients with SCLC. MK-7508 showed promising results in a phase II trial, manifested as an increased progression-free survival rate.
What are common treatments for small cell lung carcinoma?
There are several effective chemotherapy regimens for SCLC but they have limited benefit compared with supportive care alone. Radiotherapy is often used in combination with surgery and chemotherapy for people with locally advanced disease (stages III and IV), but its benefit is less clear. One review found no evidence to support chemotherapy plus radiotherapy for people whose disease has spread beyond the lungs. People with early-stage disease may benefit from adjuvant therapy; however, more research is needed before this approach can be recommended routinely. New approaches such as immunotherapy are being studied for use in conjunction with standard treatments. These treatments may improve outcomes for people with SCLC if they work by slowing growth of tumor cells or reducing their ability to invade healthy tissues.
Is mk-4830 typically used in combination with any other treatments?
MK-4830 was not commonly used in combination with other therapies In a recent study. Further research should be conducted to determine more accurately the frequency and effectiveness of MK-4830 use in combination therapies.
What is mk-4830?
Thus far, this compound has been tested in three different models of human cancers (see below). It appears to be an effective anti-cancer agent in both solid tumors and hematologic malignancies. Because of its unique mechanism of action, it may have applications beyond cancer treatment.
Can small cell lung carcinoma be cured?
To cure SCLC is an unachievable goal because of its aggressive nature and poor prognosis. Currently there are no effective therapies available for SCLC and many patients die within 3 years of diagnosis. Given the poor survival rate of SCLC patients, future research should focus on improving outcomes through innovative multimodal approaches.
What is the primary cause of small cell lung carcinoma?
Small cell lung carcinoma (SCLC) has been associated primarily with tobacco smoking. It is possible that SCLC development could be increased if there was a higher prevalence of smokers among the Patna population, particularly during childhood.